• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

癌症化疗与免疫治疗协同作用的机制。

Mechanism of synergistic effect of chemotherapy and immunotherapy of cancer.

机构信息

H. Lee Moffitt Cancer Center, MRC 2067, 12902 Magnolia Dr, Tampa, FL 33612, USA.

出版信息

Cancer Immunol Immunother. 2011 Mar;60(3):419-23. doi: 10.1007/s00262-010-0930-1. Epub 2010 Oct 26.

DOI:10.1007/s00262-010-0930-1
PMID:20976448
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11029574/
Abstract

In recent years, the combination of cancer immunotherapy with standard therapeutic modality is gaining credibility due to a number of clinical trials demonstrating therapeutic success of such combination therapies. However, the mechanism of this phenomenon is poorly understood. Here, we will discuss recent findings that suggest novel mechanisms of synergistic effect of cancer immunotherapy and chemotherapy.

摘要

近年来，由于许多临床试验证明了这种联合疗法的治疗成功，癌症免疫疗法与标准治疗方式的结合正在获得可信度。然而，这种现象的机制还了解甚少。在这里，我们将讨论最近的发现，这些发现表明了癌症免疫疗法和化疗协同作用的新机制。

相似文献

1
Mechanism of synergistic effect of chemotherapy and immunotherapy of cancer.癌症化疗与免疫治疗协同作用的机制。
Cancer Immunol Immunother. 2011 Mar;60(3):419-23. doi: 10.1007/s00262-010-0930-1. Epub 2010 Oct 26.
2
The interplay of immunotherapy and chemotherapy: harnessing potential synergies.免疫疗法和化疗的相互作用：利用潜在的协同作用。
Cancer Immunol Res. 2015 May;3(5):436-43. doi: 10.1158/2326-6066.CIR-15-0064.
3
Combining cancer vaccines with chemotherapy.将癌症疫苗与化疗相结合。
Expert Opin Pharmacother. 2005 Dec;6(16):2813-20. doi: 10.1517/14656566.6.16.2813.
4
Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy.用于癌症治疗的联合疗法，包括疫苗、化疗和单克隆抗体。
Cancer Immunol Immunother. 2009 Mar;58(3):317-24. doi: 10.1007/s00262-008-0576-4. Epub 2008 Aug 15.
5
Molecular Targets in Cancer Therapy - Fourth Biennial Meeting. Mechanism and therapeutic reversal of immune suppression in cancer.癌症治疗中的分子靶点——第四届双年会议。癌症免疫抑制的机制与治疗性逆转
IDrugs. 2007 Apr;10(4):227-9.
6
Mixed immunotherapy and chemotherapy of tumors: modeling, applications and biological interpretations.肿瘤的混合免疫疗法和化学疗法：建模、应用及生物学解释
J Theor Biol. 2006 Feb 21;238(4):841-62. doi: 10.1016/j.jtbi.2005.06.037. Epub 2005 Sep 8.
7
Are peptide vaccines viable in combination with other cancer immunotherapies?肽疫苗与其他癌症免疫疗法联合使用是否可行？
Future Oncol. 2017 Aug;13(18):1577-1580. doi: 10.2217/fon-2017-0136. Epub 2017 Aug 4.
8
Anticancer immunotherapy in combination with proapoptotic therapy.抗癌免疫疗法与促凋亡疗法联合使用。
Curr Cancer Drug Targets. 2008 Dec;8(8):666-75. doi: 10.2174/156800908786733496.
9
The Role of Hyperthermia in the Multidisciplinary Treatment of Malignant Tumors.高热在恶性肿瘤多学科治疗中的作用。
Integr Cancer Ther. 2019 Jan-Dec;18:1534735419876345. doi: 10.1177/1534735419876345.
10
Mechanisms and therapeutic potentials of cancer immunotherapy in combination with radiotherapy and/or chemotherapy.癌症免疫疗法联合放疗和/或化疗的机制及治疗潜力。
Cancer Lett. 2019 Jun 28;452:66-70. doi: 10.1016/j.canlet.2019.02.048. Epub 2019 Mar 19.

引用本文的文献

1
Emerging trends in cell-based therapies: contemporary advances and ethical considerations in translational neurosurgical oncology.基于细胞疗法的新趋势：转化神经外科肿瘤学的当代进展与伦理考量
J Neurooncol. 2025 Jul 22. doi: 10.1007/s11060-025-05170-2.
2
Adjuvant Chemoradiation and Immunotherapy for Extrahepatic Cholangiocarcinoma and Gallbladder Cancer: A Randomized Clinical Trial.肝外胆管癌和胆囊癌的辅助放化疗与免疫治疗：一项随机临床试验
JAMA Oncol. 2025 Jul 10. doi: 10.1001/jamaoncol.2025.1926.
3
Investigating the Synergistic Effects of Pembrolizumab and Chemotherapy in Gastric and Gastroesophageal Junction Cancer.探究帕博利珠单抗与化疗联合治疗胃及胃食管交界癌的协同效应。
J Gastric Cancer. 2025 Jul;25(3):455-465. doi: 10.5230/jgc.2025.25.e33.
4
Investigating the synergistic effects of immunochemotherapy in esophageal squamous cell carcinoma.研究免疫化疗在食管鳞状细胞癌中的协同作用。
Esophagus. 2025 Apr;22(2):188-197. doi: 10.1007/s10388-025-01113-y. Epub 2025 Feb 18.
5
Clinical efficacy and safety of sintilimab plus oral vinorelbine as first-line treatment for newly diagnosed stage IIIB-IV nonsmall cell lung cancer patients with performance status 2 or age ≥75 years.信迪利单抗联合口服长春瑞滨作为一线治疗体能状态为2或年龄≥75岁的初诊IIIB-IV期非小细胞肺癌患者的临床疗效和安全性。
Anticancer Drugs. 2025 Jun 1;36(5):401-407. doi: 10.1097/CAD.0000000000001699. Epub 2025 Feb 14.
6
Identifying subgroups deriving the most benefit from PD-1 checkpoint inhibition plus chemotherapy in advanced metastatic triple-negative breast cancer: a systematic review and meta-analysis.在晚期转移性三阴性乳腺癌中确定从PD-1检查点抑制联合化疗中获益最大的亚组：一项系统评价和荟萃分析
World J Surg Oncol. 2024 Dec 21;22(1):346. doi: 10.1186/s12957-024-03424-3.
7
Efficacy and safety of pembrolizumab in cervical cancer: Protocol for systematic review and meta-analysis of randomized clinical trials.帕博利珠单抗治疗宫颈癌的疗效和安全性：系统评价和随机临床试验荟萃分析方案。
PLoS One. 2024 Oct 10;19(10):e0312004. doi: 10.1371/journal.pone.0312004. eCollection 2024.
8
Chemotherapy-induced high expression of IL23A enhances efficacy of anti-PD-1 therapy in TNBC by co-activating the PI3K-AKT signaling pathway of CTLs.化疗诱导的 IL23A 高表达通过共激活 CTL 的 PI3K-AKT 信号通路增强抗 PD-1 治疗在三阴性乳腺癌中的疗效。
Sci Rep. 2024 Jun 20;14(1):14248. doi: 10.1038/s41598-024-65129-7.
9
Addition of PD-1/PD-L1 inhibitors to chemotherapy for triple-negative breast cancer: a meta-analysis.在三阴性乳腺癌化疗中添加PD-1/PD-L1抑制剂：一项荟萃分析。
Front Oncol. 2024 Feb 9;14:1309677. doi: 10.3389/fonc.2024.1309677. eCollection 2024.
10
Cytotoxic Activity of Wild Plant and Callus Extracts of and 2,3-Dihydrobenzofuran Isolated from a Callus Culture.从愈伤组织培养物中分离得到的野生植物及愈伤组织提取物以及2,3-二氢苯并呋喃的细胞毒性活性。
Pharmaceuticals (Basel). 2023 Oct 3;16(10):1400. doi: 10.3390/ph16101400.

本文引用的文献

1
Combination of intensive chemotherapy and anticancer vaccines in the treatment of human malignancies: the hematological experience.强化化疗与抗癌疫苗联合治疗人类恶性肿瘤：血液学经验
J Biomed Biotechnol. 2010;2010:692097. doi: 10.1155/2010/692097. Epub 2010 Jun 2.
2
Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice.化疗增强了癌症免疫治疗中 CTL 介导的杀伤肿瘤细胞的敏感性。
J Clin Invest. 2010 Apr;120(4):1111-24. doi: 10.1172/JCI40269. Epub 2010 Mar 15.
3
Dual therapeutic efficacy of vinblastine as a unique chemotherapeutic agent capable of inducing dendritic cell maturation.长春碱作为一种能够诱导树突状细胞成熟的独特化疗药物具有双重治疗效果。
Cancer Res. 2009 Sep 1;69(17):6987-94. doi: 10.1158/0008-5472.CAN-09-1106. Epub 2009 Aug 25.
4
Chemotherapeutic agents in noncytotoxic concentrations increase antigen presentation by dendritic cells via an IL-12-dependent mechanism.非细胞毒性浓度的化疗药物通过白细胞介素-12依赖机制增加树突状细胞的抗原呈递。
J Immunol. 2009 Jul 1;183(1):137-44. doi: 10.4049/jimmunol.0900734. Epub 2009 Jun 17.
5
Cell-surface expression of Hsp70 on hematopoietic cancer cells after inhibition of HDAC activity.HDAC活性抑制后造血癌细胞上Hsp70的细胞表面表达
J Leukoc Biol. 2009 Oct;86(4):923-32. doi: 10.1189/jlb.0209056. Epub 2009 Jun 5.
6
Immunogenic and tolerogenic cell death.免疫原性和耐受性细胞死亡
Nat Rev Immunol. 2009 May;9(5):353-63. doi: 10.1038/nri2545.
7
Cancer vaccines: moving beyond current paradigms.癌症疫苗：超越当前范式
Clin Cancer Res. 2007 Jul 1;13(13):3776-82. doi: 10.1158/1078-0432.CCR-07-0588.
8
Mechanism and therapeutic reversal of immune suppression in cancer.癌症免疫抑制的机制与治疗性逆转
Cancer Res. 2007 Jun 1;67(11):5067-9. doi: 10.1158/0008-5472.CAN-07-0897.
9
Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications.硼替佐米通过使垂死肿瘤细胞表面的热休克蛋白90暴露，增强树突状细胞（DC）介导的对人骨髓瘤的免疫诱导：治疗意义。
Blood. 2007 Jun 1;109(11):4839-45. doi: 10.1182/blood-2006-10-054221. Epub 2007 Feb 13.
10
A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer.一项关于多西他赛联合疫苗与单纯疫苗治疗转移性去势抵抗性前列腺癌的随机II期研究。
Clin Cancer Res. 2006 Feb 15;12(4):1260-9. doi: 10.1158/1078-0432.CCR-05-2059.